Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

NCT03647358 — Phase 1, Recruiting, 75 participants, Memorial Sloan Kettering Cancer Center

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Registry	NCT03647358
Status	Recruiting
Phase	Phase 1
Study type	Interventional; na, single group, masking: none, diagnostic
Enrollment	75 (Estimated)
Sponsor	Memorial Sloan Kettering Cancer Center (Other)
Conditions	Thyroid Carcinoma, Metastatic Thyroid Carcinoma
Interventions	PET/CT Scan, Iodine-124 (Device, drug)
Dates	start 2018-08-21, primary completion 2027-08-01 (estimated), completion 2027-08-01 (estimated), first posted 2018-08-27, last updated 2026-09-10
Locations	1 site in United States

-Summary

The purpose of this study is to evaluate a new diagnostic imaging test, positron emission tomography (PET), with a different radioactive form of iodine called iodine-124. This form is able to accurately measure the amount of radioactive iodine uptake in the cancer. If the new test determines sufficient radioiodine uptake in the cancer, treatment will continue as usual. However, if the new test shows only low radioiodine uptake, a decision may be made that the benefit from radioiodine therapy is insufficient and that another form of therapy is preferred.

Expand all sections · Collapse all

+Arms and interventions

Arm	Type	Interventions	Description
Lesion Dosimetry With Iodine-124	Experimental	Device: PET/CT Scan; Drug: Iodine-124	Patients will be administered 124I and undergo serial PET imaging consisting of up to 4 individual PET/CT scans. In order to perform a dual exponential fit, 4 scans are needed to obtain the necessary amount of data points required. Lesion dosimetry shall be performed based on the 124I PET scan data through tumor uptake and clearance pharmacokinetics. 10 patients, who sign consent for the sub-study, will be administered an additional tracer diagnostic activity of 124I (4 to 7 mCi). These patients will then undergo additional (up to a maximum of 4) PET scanning during radioiodine therapy at time points matched, if possible, to the days of the pre-therapy 124I dosimetry study.

PET/CT Scan (Device): Up to four whole-body PET scans (approximately 24, 48, and 120 hours post 124I oral dose) will be performed on one of the GE Discovery 710 or 690 PET scanners.
Iodine-124 (Drug): Patients will receive 0.9 mg injections of rhTSH on two consecutive days. Twenty-four hours after the last injection of rhTSH each patient will receive approximately 5 mCi (range: 4-7 mCi) of 124I orally as a single dose. (If a holiday is present in the work week, 124I can be administered orally on Day 2, if needed).

+Outcome measures

Primary outcomes

number of individual lesions response [1 year]: This will be accomplished using a logistic regression model using lesion as the unit of analysis and adjusting for possible correlation between lesions on the same patient using a random effect at the patient level. by RECIST 1.1

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Adults with thyroid carcinoma confirmed by pathology.
* Adult thyroid carcinoma patients who have undergone total thyroidectomy
* Adult thyroid carcinoma patients have metastatic disease or suspicion for metastatic disease, or are under a protocol intended to explore re-induction therapy for 131I uptake, and are about to undergo Thyrogen-assisted dosimetry, unless Thyrogen-assisted dosimetry is not required per standard of care.
* The patient and physician are planning to administer 131I for therapy if persistent radioiodine-avid metastases are present.
* All subjects must have measurable disease, documented within the previous six months by ultrasonography (US), MRI, FDG PET/CT, or CT scanning.

Exclusion Criteria:

* Age less than 18 years.
* Patients who are pregnant.

+Locations (1)

Facility	City	Country	Status
Memorial Sloan Kettering Cancer Center	New York, New York	United States	Recruiting

+Publications

Results publication: Mauguen A, Grewal RK, Augensen F, Abusamra M, Mahajan S, Jayaprakasam VS, Osborne J, Haque S, Wong BZY, Ghossein RA, Fagin J, Schӧder H, Tuttle RM, Ho A, Humm JL, Larson SM. The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients. Eur J Nucl Med Mol Imaging. 2023 Aug;50(10):2971-2983. doi: 10.1007/s00259-023-06240-1. Epub 2023 May 12. PMID 37171634

+Investigators

Ravinder Grewal, MD, Principal investigator, Memorial Sloan Kettering Cancer Center

My Notes

Public

To Read Reading Read